VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?

Veracyte, Inc. VCYT shares have fallen 25.3% in the past month even as the diagnostics company continues to post double-digit testing growth and stronger earnings. Second-quarter 2026 revenues rose 15.4% year over year, while adjusted earnings increased 22.7%.

The sell-off has improved the entry price, but valuation and commercialization risks still matter. Investors must weigh durable demand for Decipher and Afirma, newer oncology launches and positive estimate revisions against reimbursement uncertainty and execution demands.

VCYT’s Core Tests Still Show Strong Demand

Decipher Prostate remains the largest growth engine. Second-quarter revenues increased 20% year over year to $91.9 million as test volume rose 17% to about 29,700. Orders per physician reached a record high, while new ordering physicians also increased.

Afirma added another layer of growth. Second-quarter revenues climbed 18% as volume rose 10% to about 18,600 tests, supported by higher utilization, share gains and better reimbursement. Veracyte expects Afirma revenues to increase about 12% to 14% in 2026.

Veracyte’s New Launches Expand the Growth Runway

Veracyte launched Prosigna LDT in the United States in the second quarter after presenting results from the OPTIMA Phase III trial. The company is engaging with more than 100 institutions and is expanding its sales force ahead of plan.

Based on short-term price targets offered by 11 analysts, the average price target for Veracyte comes to $57.82. The average price target represents an increase of 36.66% from the last closing price of $42.31.

Image Source: Zacks Investment Research

TrueMRD, launched in June for muscle-invasive bladder cancer, already has Medicare coverage for recurrence monitoring after radical cystectomy. The competitive field is active. Natera, Inc. NTRA has an FDA-approved Signatera companion diagnostic for molecular residual disease in muscle-invasive bladder cancer, while Guardant Health, Inc. GH is expanding liquid-biopsy and recurrence-monitoring capabilities across oncology.

VCYT Faces Reimbursement and Execution Risks

Prosigna has not yet secured Medicare reimbursement, and Veracyte excluded both Prosigna LDT and TrueMRD revenues from 2026 guidance because commercialization remains early. Decipher also faces softer demand in low-risk prostate cancer following guideline changes.

The Veracyte SAS exit adds another reset. Biopharmaceutical and other revenues fell to $0.8 million in the second quarter from $4.3 million a year earlier, increasing dependence on testing revenues. Higher investment adds execution pressure, with non-GAAP research and development expense rising to $26.3 million from $14.3 million.

Veracyte’s Valuation Leaves Less Room for Error

The recent decline has not made VCYT inexpensive relative to its group. The stock trades at 5.3X forward 12-month sales, above the Zacks sub-industry’s 4.2X multiple and slightly above its five-year median of 5.2X.

Image Source: Zacks Investment Research

That premium leaves less room for setbacks in reimbursement or launch execution. Still, the balance sheet provides flexibility. Veracyte ended the second quarter with $485.2 million in cash, cash equivalents and short-term investments and no current debt.

VCYT’s Signals Mix Strength With Caution

The sell-off has created a better price than a month ago, but the case is not purely valuation driven. Core test demand, raised 2026 revenue guidance and a debt-free balance sheet support the operating outlook, while reimbursement and commercialization risks argue for selectivity.

VCYT currently carries a Zacks Rank #1 (Strong Buy), reflecting favorable near-term earnings-estimate revisions. The Zacks Consensus Estimate for 2026 earnings has risen 3.9% in the past four weeks. Its Momentum Score of B is supportive, but the Growth Score of C, Value Score of D and VGM Score of D show that the stock does not score favorably across all investing styles. The combination points to stronger near-term estimate momentum, tempered by valuation and broader style considerations.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research